Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. (PubMed, Br J Haematol) - No abstract available

Journal • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

RESULTS FROM THE DOSE-FINDING PART OF LuminICE-203 PHASE 2 STUDY: ACIMTAMIG (AFM13) IN COMBINATION WITH AlloNK (AB-101) IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA (ICML 2025) - P2 | "Introduction: New therapeutic options are needed for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who progress following standard systemic therapies including chemotherapy, brentuximab vedotin (BV), and checkpoint inhibitors. The combination of acimtamig and AlloNK has shown promising efficacy with a well-managed safety profile, indicating potential therapeutic benefits and offering hope for patients with R/R cHL who have exhausted standard-of-care treatment options."

Clinical • Combination therapy • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • FCGR3A • TNFRSF8

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers. (PubMed, Eur J Haematol) - P | "BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. In Ya&A with high-risk cHL, our data suggest that a BV-driven strategy (without bleomycin and consolidation radiotherapy) is an effective up-front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500."

Journal • Cardiovascular • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma. (PubMed, Blood) - P1/2 | "The 36-month PFS (from first scan) was 73.0% (54.5, 85.0) for BV/Ipi/Nivo compared to 45.8% (26.3, 63.4) for BV/Nivo (HR=0.45, CI 0.19-1.08, one-sided p=0.03). The study did not meet its primary endpoint of superior CR rate for the triplet, but it supports the use of checkpoint-ADC induction prior to auto SCT, and there is an intriguing signal of disease control for patients wishing to defer or avoid SCT for the triplet of BV/Ipi/Nivo."

Journal • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation • TNFRSF8

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. (PubMed, J Clin Oncol) - P3 | "PET-guided BrECADD in older patients is feasible and effective. With a PFS rate on par with that of younger patients, short duration, and limited anthracycline exposure, BrECADD is a valuable treatment option also for older patients with AS-cHL."

Journal • P2 data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lymphoma • Neutropenia • Oncology • Thrombocytopenia

Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma (ASH 2025) - P1 | "HL pts received standard dosesof a lymphodepletion chemotherapy (LDC) regimen (Flu/Cy or bendamustine was allowed per protocol)for three consecutive days (Day -5 to Day -3) before infusion of MT-601 (MT-601 doses: 200 x106 cells n=3; 300 x106 cells n=2; 400 x106 cells n=4). Initial disease assessment was conducted 8 weeks post MT-601infusion.The 9 HL pts (female n=4; male n=5) had a median age of 43 (range 30-75) and had undergone a medianof 8 prior lines of therapy, with all 9 pts having received prior brentuximab, PD-1 and HSCT (autologousn=5; allogeneic n=2; autologous and allogeneic n=2)...These preliminary findings from the Phase 1 APOLLO study demonstrate that MT-601 has a favorablesafety profile and early objective responses in heavily pre-treated HL pts. The encouraging tolerability ina population with limited treatment options supports the potential of MT-601 to address a significantunmet medical need and warrants further clinical examination. We will..."

Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Hodgkin Lymphoma • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Immunodeficiency • BIRC5 • CTAG1B • MAGEA4 • PD-1 • PRAME • WT1

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL) (ASH 2025) - "We assessed PROs in S1826, a trial showingthat nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) resulted in longer progression-free survival compared to brentuximab vedotin plus AVD (BV+AVD). Trial results support the feasibility ofserial collection of PROs, as indicated by high response rates, despite participants' advanced stagedisease and broad institutional participation. Future analyses will address the planned 3-year outcomesas well as formal evaluation of missing data."

Clinical • Metastases • P3 data • Patient reported outcomes • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma (ASH 2025) - P3 | "Introduction The German Hodgkin Study Group (GHSG) HD21 trial for adult patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (AS-cHL) was designed to reduce treatment-related morbidity (TRMB)and improve efficacy by comparing the novel BrECADD regimen (brentuximab vedotin, etoposide,cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to the standard eBEACOPP protocol.Here, we report the final efficacy and safety including long-term progression-free survival (PFS), overallsurvival (OS), and late toxicity outcomes. While higher baseline lymphoma burden associates with incomplete remission atPET2, the risk for treatment failure seems mitigated through response-adaptation. Taken together, ourresults establish individualized BrECADD as a standard treatment option for adult patients with newlydiagnosed AS-cHL."

Metastases • P3 data • Acute Myelogenous Leukemia • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

BC2: Beyond the ABVDs of Hodgkin Lymphoma: PET-Adaptive and Targeted Therapy (HOPA 2026) - "The addition of Nivolumab-AVD, Brentuximab vedotin (BV)-AVD, and BrECADD as preferred regimens and the introduction of PET-adapted treatment has changed the treatment landscape of newly-diagnosed Stage III-IV HL. Additionally, the implementation of PET-adapted therapy in late stage newly-diagnosed patients will be explored. UAN: 0465-0000-26-008-L01-P Knowledge or Application Based: Application Learning Objectives: Describe the clinical presentation and pathological features of classical Hodgkin Lymphoma (cHL)Analyze pivotal clinical trial data for novel treatment strategies in newly- diagnosed, advanced stage cHLSelect the appropriate initial therapy for a patient with newly-diagnosed, advanced stage cHLDesign a therapy plan for a patient with newly-diagnosed, advanced stage cHL based on interim PET resultsEvaluate clinical trial data on targeted agents in relapsed/refractory cHL"

Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Are CHOP-Plus Really CHOP-Minus Propositions in the Treatment of PTCL? A Comprehensive Assessment of the Strategy. (PubMed, Blood Adv) - "Despite this, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOP-like regimens remain the standard frontline therapy-even though pivotal studies establishing CHOP in NHL included only B-cell patients, with no evidence for PTCL. Outside of anaplastic large cell lymphoma (ALCL), where brentuximab vedotin has improved survival, this approach has generally failed; in most PTCL subtypes, 5-drug regimens add toxicity without clear benefit. After two decades of disappointing results, this review critically examines the evidence, the limitations of current strategies, and opportunities to rethink future approaches."

Journal • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASTRO 2025) - "16 (89%) received doxorubicin/hydroxydaunorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the three patients currently in remission included pembro plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1)... Pembro-RT yielded excellent CMR rates and minimal toxicity. These data suggest pembro-RT as a potential alternative to high dose chemo and SCT in localized, favorable relapsed/refractory HL. Enrollment to the study is complete and data will be updated prior to the meeting."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma (ASH 2025) - "Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients(pts) with previously untreated advanced stage (AS) classic Hodgkin lymphoma (cHL), PD-1 blockade withnivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) prolongedprogression-free survival (PFS) compared with standard brentuximab vedotin (BV) combined with AVD ata median follow-up of 2 years. The benefit of N-AVD compared to BV-AVD in adolescent and adult pts with AS cHL issustained with 3y follow-up, including all pre-specified age, stage, and IPS risk subgroups. This updatedemonstrates the durability of remissions with N-AVD over time without any new safety signals, andenables benchmarking with other modern cHL trials. Follow-up will continue to evaluate for latetoxicities, OS, and PROs."

Metastases • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Skin Cancer • Solid Tumor

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

Cellular and Novel Immunotherapies for Classic Hodgkin Lymphoma. (PubMed, Hematol Oncol Clin North Am) - "The CD30 antibody-drug conjugate, brentuximab vedotin, and PD-1 inhibitors, nivolumab and pembrolizumab have transformed the care of patients with Hodgkin lymphoma and have been incorporated into earlier lines of therapy. Novel immunotherapies for patients with relapsed/refractory Hodgkin lymphoma include CAR-T products, EBV-specific T cells, bispecific antibodies, and checkpoint inhibitor combinations. We review the rationale for each and summarize safety, efficacy, and progress in clinical development."

Journal • Review • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • TNFRSF8

Comparison of Contemporary Radiotherapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331. (PubMed, Int J Radiat Oncol Biol Phys) - "Selective use of RT combined with chemotherapy, including brentuximab vedotin, led to excellent outcomes for pediatric patients with high-risk HL. Proton therapy utilization increased during the study, showing similar disease control and toxicity outcomes as 3D-CRT and IMRT. Long-term follow-up is essential to evaluate the risks of secondary malignancies and cardiac toxicity across radiation techniques."

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

MARIBAVIR TREATMENT IN AGGRESSIVE EBV-ASSOCIATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+ PTLD) (EBMT 2026) - "She received the VCAP-AMP-VECP regimen plus intrathecal chemotherapy for 4 cycles with Ropeginterferon alfa-2b for skin involvement...GVHD prophylaxis with cyclosporine and mycophenolate was tapered within three months due to Pneumocystis jirovecii pneumonitis...Treatment included carmustine, brentuximab vedotin, venetoclax, azacitidine, and two donor lymphocyte infusions (5M/kg CD3+ T cells each). She developed severe liver and GI GVHD (bilirubin 15.4 mg/dL), requiring steroids, tacrolimus, mycophenolate, abatacept, ATG (1mg/kg), and ruxolitinib (40mg daily)... Approximately half of EBV+ PTLD cases show relapse or resistance to initial RIS or Rituximab-based treatments. While no clinical trials have proven maribavir efficacy in EBV+ PTLD, this case demonstrates promising results in a complex post-transplant setting with multiple complications, highlighting the need for further research in this unmet medical need."

Post-transplantation • Adult T-Cell Leukemia-Lymphoma • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Obesity • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) (EHA 2025) - P1, P3 | "All patients had received chemotherapy regimens; moreover, all patients had been treated with tucidinostat or brentuximab vedotin (tucidinostat, 59 [88.1%]; brentuximab vedotin, 21 [31.3%]; both, 13 [19.4%]). The pivotal study met its primary endpoint, demonstrating that SHR2554 is efficacious and has a manageable safety profile in patients with r/r PTCL. Our findings position SHR2554 as a new potential therapeutic option for this challenging-to-treat population. A randomized controlled phase 3 study comparing SHR2554 with standard therapy for r/r PTCL is currently underway (ClinicalTrials.gov, NCT06122389)."

Anemia • Hematological Disorders • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • EZH2

Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826 (ASH 2025) - "In the S1826 phase III trial, patients (pts) with newlydiagnosed advanced stage cHL who were treated with nivolumab (N)-AVD, vs brentuximab-vedotin (BV)-AVD, had improved progression-free survivals (PFS), establishing a new standard of care. In S1826, ctDNA-guided analyses of MTB enabled early risk stratification at C3D1 andstrongly outperformed PET assessments at EOT. Future prospective studies should incorporate ctDNAanalyses of MTB to improve precision therapy in cHL."

Circulating tumor DNA • Clinical • IO biomarker • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

2-YEAR FOLLOW-UP OF THE S1826 STUDY CONFIRMS IMPROVED PROGRESSION-FREE SURVIVAL WITH NIVOLUMAB-AVD COMPARED TO BRENTUXIMAB VEDOTIN-AVD IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA (ISHL 2024) - "We hypothesized that introducing PD-1 blockade with nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) would improve progression-free survival (PFS) over BV-AVD in AS cHL and evaluated this approach in the randomized, phase 3 S1826 study. N-AVD was better tolerated and improved PFS versus BV-AVD in adolescent and adult pts with AS cHL. Longer follow-up confirmed the PFS benefit with N-AVD at 2 y, including pre-specified subgroups. N-AVD is a new standard of care for treatment of AS cHL."

Metastases • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Pediatrics • Pneumonia

High efficacy and durability of second-line therapy with pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma (ISHL 2022) - "36 pts proceeded to HDT/AHCT of whom 13 (36%) received post-transplant brentuximab vedotin (BV) (n=12) or BV plus nivolumab (bv/nivo) (n=1) maintenance. Second-line therapy with P-GVD is highly effective and efficiently bridges pts with RR cHL to HDT/AHCT. With extended follow-up for transplanted pts, remissions remain durable with estimated 30-month PFS of 96%. Among 68 evaluable pts enrolled onto parts I and II, CR rate remains high at 92.6%."

Clinical • P2 data • Anemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Inflammation • Lymphoma • Mucositis • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412) (ASH 2023) - "In this randomized Phase 2 study comparing BV/N vs. BV/ N/I the difference in CR rate of 6.7% between the doublet and the triplet was not statistically significant. Additionally, the triplet had more grade 3 rash than the doublet, there was otherwise no significant difference in grade 3 or greater toxicity between the two arms."

Clinical • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • TNFRSF8